[go: up one dir, main page]

WO2008121160A3 - Optimized antibodies that target cd5 - Google Patents

Optimized antibodies that target cd5 Download PDF

Info

Publication number
WO2008121160A3
WO2008121160A3 PCT/US2007/083247 US2007083247W WO2008121160A3 WO 2008121160 A3 WO2008121160 A3 WO 2008121160A3 US 2007083247 W US2007083247 W US 2007083247W WO 2008121160 A3 WO2008121160 A3 WO 2008121160A3
Authority
WO
WIPO (PCT)
Prior art keywords
target
antibodies
optimized antibodies
parent antibody
alters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/083247
Other languages
French (fr)
Other versions
WO2008121160A2 (en
Inventor
Matthew J Bernett
John R Desjarlais
Sher Bahadur Karki
Eugene Alexander Zhukovsky
Erik Weiking Pong
Seung Yup Chu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xencor Inc
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc filed Critical Xencor Inc
Publication of WO2008121160A2 publication Critical patent/WO2008121160A2/en
Publication of WO2008121160A3 publication Critical patent/WO2008121160A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcgR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
PCT/US2007/083247 2006-11-21 2007-10-31 Optimized antibodies that target cd5 Ceased WO2008121160A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86679306P 2006-11-21 2006-11-21
US60/866,793 2006-11-21

Publications (2)

Publication Number Publication Date
WO2008121160A2 WO2008121160A2 (en) 2008-10-09
WO2008121160A3 true WO2008121160A3 (en) 2009-01-22

Family

ID=39808822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/083247 Ceased WO2008121160A2 (en) 2006-11-21 2007-10-31 Optimized antibodies that target cd5

Country Status (1)

Country Link
WO (1) WO2008121160A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
LT2708559T (en) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2760642A1 (en) 2009-05-01 2010-11-04 The University Of Tokyo Anti-cadherin antibody
WO2011089211A1 (en) * 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
CA2799595C (en) 2010-05-27 2022-08-16 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
TWI656133B (en) 2014-12-19 2019-04-11 日商中外製藥股份有限公司 Anti-myostatin antibody, multi-peptide containing variant Fc region and method of use
CA2974547A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
TWI693940B (en) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Composition for the treatment or prevention of IL-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
MX2020004910A (en) * 2017-11-29 2020-10-05 Magenta Therapeutics Inc COMPOSITIONS AND METHODS FOR DEPLETION OF CD5 + CELLS.
SG11202009010RA (en) 2018-03-15 2020-10-29 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
CA3102398A1 (en) 2018-06-03 2019-12-12 Lamkap Bio Beta Ltd. Bispecific antibodies against ceacam5 and cd47
CA3107383A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
EP3915641A1 (en) * 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5 antibodies and methods of use thereof
EP4200335A4 (en) * 2020-08-21 2024-10-02 City of Hope ANTI-CD5 ANTIBODY COMPOSITIONS AND THEIR USES
US20240041932A1 (en) 2020-09-14 2024-02-08 Vor Biopharma Inc. Compositions and methods for cd5 modification
US20250179172A1 (en) * 2020-12-17 2025-06-05 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Cd5 antibody and use thereof
EP4055055B1 (en) 2020-12-18 2023-11-22 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
WO2022152185A1 (en) * 2021-01-12 2022-07-21 南京驯鹿医疗技术有限公司 Cd5-targeting fully humanized antibody
CN113105547B (en) * 2021-05-18 2022-04-08 福州迈新生物技术开发有限公司 anti-CD 5 protein monoclonal antibody and cell strain, preparation method and application thereof
US12077597B2 (en) 2021-11-24 2024-09-03 International-Drug-Development-Biotech Anti-CD5 antibodies and methods of use thereof
AU2023291779A1 (en) 2022-06-16 2024-10-17 Lamkap Bio Beta Ltd Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008883A1 (en) * 2003-12-04 2006-01-12 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2006105338A2 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008883A1 (en) * 2003-12-04 2006-01-12 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2006105338A2 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTIN J H ET AL: "Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies.", BLOOD 15 OCT 1991, vol. 78, no. 8, 15 October 1991 (1991-10-15), pages 2139 - 2149, XP002505318, ISSN: 0006-4971 *
CIOCA D P ET AL: "Apoptosis induction by hypercross-linking of the surface antigen CD5 with anti-CD5 monoclonal antibodies in B cell chronic lymphocytic leukemia.", LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K MAR 2002, vol. 16, no. 3, March 2002 (2002-03-01), pages 335 - 343, XP002505317, ISSN: 0887-6924 *
PERS J O ET AL: "CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia.", LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K JAN 2002, vol. 16, no. 1, January 2002 (2002-01-01), pages 44 - 52, XP002505316, ISSN: 0887-6924 *
STUDNICKA G M ET AL: "HUMAN-ENGINEERED MONOCLONAL ANTIBODIES RETAIN FULL SPECIFIC BINDINGACTIVITY BY PRESERVING NON-CDR COMPLEMENTARITY-MODULATING RESIDUES", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 7, no. 6, 1 June 1994 (1994-06-01), pages 805 - 814, XP000447301, ISSN: 0269-2139 *

Also Published As

Publication number Publication date
WO2008121160A2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
WO2008121160A3 (en) Optimized antibodies that target cd5
WO2008022152A3 (en) Optimized antibodies that target cd19
WO2008091798A3 (en) Optimized ca9 antibodies and methods of using the same
WO2008091954A3 (en) Optimized cd40 antibodies and methods of using the same
WO2008098115A3 (en) Optimized igf-1r antibodies and methods of using the same
WO2007044616A3 (en) Optimized anti-cd30 antibodies
WO2009026117A3 (en) Novel compounds
WO2007024846A3 (en) Anit-il-23 antibiodies
WO2008036688A3 (en) Optimized antibodies that target hm1.24
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
WO2005092925A3 (en) Immunoglobulin variants outside the fc region
WO2004072266A3 (en) Antibody affinity engineering by serial epitope-guided complementarity replacement
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2009070243A3 (en) Wise binding antibodies and epitopes
WO2006130374A3 (en) Tweak binding antibodies
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
WO2008094538A3 (en) Regulatory t cell epitopes, compositions and uses thereof
WO2009081285A3 (en) Hepatitis c virus antibodies
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
WO2008143697A3 (en) Antibody with protein a selectivity
WO2008140570A3 (en) Antibody with protein a selectivity
WO2007127506A3 (en) Anti-ephrinb2 antibodies and methods using same
WO2006135527A3 (en) Methods for the selection of aptamers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07873582

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07873582

Country of ref document: EP

Kind code of ref document: A2